Indeed, the standard of care for APL harboring the PML-RARA fusion is either all-trans-retinoic acid (ATRA) or arsenic trioxide, both of which lead to the degradation of the PML-RARA fusion protein61–65. This evidence concerns the gene RARA and acute promyelocytic leukemia.